Japan regulates medical devices under the Pharmaceuticals and Medical Devices Act (PMD Act), administered by the Ministry of Health, Labour and Welfare (MHLW) and reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA). Devices are classified into Classes I to IV with escalating review requirements. A foreign manufacturer cannot hold a Japanese marketing authorisation directly; they must appoint a Marketing Authorisation Holder (MAH) or a Designated Marketing Authorisation Holder (D-MAH) established in Japan. Japan is a high-value but high-effort market that rewards sequencing after CE mark and, often, after FDA clearance.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • Japan's medical device framework is the PMD Act, with PMDA as the review agency and MHLW as the approving ministry.
  • Classification is four-tier (Class I general, Class II controlled, Class III and Class IV specially controlled), with review pathways scaled to risk.
  • Foreign manufacturers must appoint a Marketing Authorisation Holder (MAH) or Designated MAH (D-MAH) based in Japan to hold the approval on their behalf.
  • Japanese evidence expectations emphasise quality system audits, clinical data relevance to Japanese populations, and rigorous technical documentation often translated into Japanese.
  • Japan recognises Quality Management System Regulation (QMS Ministerial Ordinance No. 169) which is closely aligned with ISO 13485, reducing QMS rebuild effort for CE-marked manufacturers.
  • Typical Japan market entry for an EU startup takes 12 to 36 months after CE mark, depending on device class and clinical data strategy.
  • Japan is rarely an EU startup's second market; it usually comes after the US and sometimes after selected EU national wins.

Why this matters

Japan is one of the three largest medical device markets globally and one of the most demanding regulatory environments. Hospitals, reimbursement systems and clinicians in Japan expect a standard of documentation and evidence quality that rewards disciplined EU startups and punishes those who try to treat Japan as "CE mark with translation."

For EU MedTech founders, Japan is often misunderstood in two directions. Some founders dismiss it as impossibly complex and never attempt entry. Others assume their MDR technical file translates directly and are surprised by rework. The truth sits between: Japan is manageable with the right MAH partner and realistic sequencing, and it pays well for devices that address Japanese clinical priorities, but it is not a market you enter casually.

What Japanese law actually requires

The Pharmaceuticals and Medical Devices Act (PMD Act) is the primary Japanese legislation governing medical devices, pharmaceuticals, cosmetics and regenerative medicine. It was formally renamed from the older Pharmaceutical Affairs Law (PAL) in 2014 to reflect an expanded scope and dedicated medical device provisions.

PMDA (Pharmaceuticals and Medical Devices Agency) is the scientific review agency that evaluates submissions. MHLW (Ministry of Health, Labour and Welfare) is the ministry that grants approvals based on PMDA's review.

Japanese medical device classification follows a four-tier risk-based system:

  • Class I — General medical devices. Low-risk devices. Require self-declaration (pre-market submission) to PMDA. Minimal review burden.
  • Class II — Controlled medical devices. Moderate risk. For devices with a relevant Japanese certification standard, review is delegated to a Registered Certification Body (RCB) under a pathway called Ninsho. For devices without an applicable standard, PMDA reviews directly (Shonin).
  • Class III — Specially controlled medical devices. Higher risk. Most require PMDA review (Shonin) with more extensive clinical and technical justification.
  • Class IV — Specially controlled medical devices, highest risk. Implantables, life-supporting devices and similar. PMDA review, often with clinical data generated in or relevant to Japanese populations.

Central to the Japanese framework is the concept of the Marketing Authorisation Holder (MAH, in Japanese "Seizo-Hanbai-Gyo"). A foreign manufacturer cannot hold a Japanese marketing authorisation directly. A Japanese legal entity must hold the authorisation and assume defined regulatory, vigilance and quality oversight responsibilities. Two common structures:

  • MAH. A Japanese subsidiary of the foreign manufacturer, holding the authorisation in-house.
  • D-MAH (Designated MAH). A third-party Japanese entity (often a specialised service provider or Japanese distributor with the required licences) that holds the authorisation on behalf of the foreign manufacturer. This is the common route for EU startups entering Japan before they have their own presence.

The MAH must have the required Japanese business licences (typically a Type 1 licence for the highest device classes, descending Type numbers for lower risks). The MAH handles submissions to PMDA, maintains vigilance reporting to MHLW, and is legally responsible for products in Japan.

Japanese quality system requirements are set out in MHLW Ministerial Ordinance No. 169 (often referred to as the QMS Ministerial Ordinance), which is closely aligned with ISO 13485. For manufacturers with a mature EN ISO 13485:2016+A11:2021 QMS, the delta is manageable and focuses mainly on Japan-specific record-keeping and MAH interface processes.

A worked example

A Zurich-based Class IIa (MDR) cardiology software startup has a CE mark, an FDA 510(k) clearance, and 18 months of European commercial revenue. The board asks about Japan. The founders run the numbers.

Japanese classification for their software likely maps to Class II (controlled) under the PMD Act framework. A Japanese certification standard exists for the relevant functional category, so the pathway is Ninsho (RCB review) rather than direct PMDA Shonin review. This is good news: the timeline and cost profile is lower.

They evaluate three potential D-MAH partners. One is a large Japanese MedTech distributor with broad scope but limited software experience. Two are specialised regulatory service providers with dedicated SaMD practices. They choose one of the specialised providers based on reference calls with two prior EU software clients.

The D-MAH leads an engagement plan: - Gap analysis of the existing MDR and 510(k) technical documentation against Japanese submission requirements (six weeks). - Translation of key technical file sections into Japanese (eight weeks, overlap). - Preparation of the Ninsho submission package (10 weeks). - RCB review (three to six months). - Post-approval labeling finalisation, QMS ordinance alignment documentation, and vigilance flow setup (four weeks, overlap). - Total elapsed time from kickoff to approval: 12 to 18 months. - Total cost: 150,000 to 300,000 EUR, including D-MAH fees, translation, RCB fees, internal time and travel.

The device launches in Japan 24 months after the initial board discussion. First-year Japan revenue covers the approval investment within the first 18 months of sales. This is what a well-sequenced Japan entry looks like for an EU software startup.

Now the counter-example. A hardware Class III implantable startup takes the same board decision. Japanese classification is Class IV. Pathway is direct PMDA Shonin review. Japanese clinical data expectations are high, often requiring a Japan-specific clinical study or at minimum a rigorous bridging analysis showing that existing data applies to Japanese populations. Timeline: 30 to 48 months. Cost: 1 to 5 million EUR. This is not impossible, but it is a different scale of commitment and usually not an early-stage EU startup move.

The Subtract to Ship playbook for Japan

Step one. Confirm the strategic rationale. Japan rewards devices with clear clinical benefit, Japanese clinical priorities (ageing population, cardiovascular, orthopaedic, ophthalmology, diagnostics), and a realistic distribution plan. Do not enter Japan because it sounds impressive; enter because the commercial opportunity justifies the cost.

Step two. Map your device to Japanese classification. Use the existing Japanese classification nomenclature (JMDN codes) to identify likely Class and applicable certification standards. This determines whether your route is Ninsho (RCB) or Shonin (PMDA) and shapes every downstream decision.

Step three. Select a D-MAH partner with relevant device experience. Evaluate on: - Prior approvals for similar device types in the last 24 months - SaMD experience if your device is software - Quality of their Japanese regulatory writing - Transparency of fee structures - Handling of post-approval vigilance and PMDA correspondence - Willingness to work under a clear written mandate

Step four. Do an honest gap analysis between your MDR technical documentation and the Japanese submission requirements. Reusable elements usually include risk management, software lifecycle documentation (EN 62304), usability engineering (EN 62366-1), biocompatibility where applicable, and the core clinical evaluation. Rewrites or translations usually hit the device description, intended use, labeling, clinical relevance to Japan, and Japan-specific QMS records.

Step five. Plan translation early. Japanese regulatory documents are not a post-hoc activity. Key technical file sections, labeling, IFU and MAH-facing documents need competent medical regulatory translation, ideally by translators with prior PMDA submission experience.

Step six. Align your QMS to Ministerial Ordinance No. 169 gaps. For most EN ISO 13485:2016+A11:2021-certified manufacturers this is a documentation exercise rather than a process rebuild.

Step seven. Build the Japan vigilance flow into your post-market surveillance SOP. Serious events involving Japanese users flow through the MAH to PMDA/MHLW under defined timelines.

Step eight. Sequence carefully. Japan rarely comes first for EU startups. A healthy sequence is often CE mark → commercial revenue in EU → FDA clearance → Japan. This sequence uses FDA documentation as a stepping stone, reduces cost of duplication, and ensures Japan entry is funded by real prior revenue rather than pre-emptive burn.

Reality Check

  1. Do you have a commercial rationale for Japan that is specific to the Japanese clinical and payer environment, not just "Japan is a big market"?
  2. Have you mapped your device to a likely Japanese class and JMDN code?
  3. Do you know whether your pathway is Ninsho (RCB) or Shonin (PMDA)?
  4. Have you identified at least two D-MAH candidates with directly relevant experience?
  5. Do you have a realistic budget and timeline model for Japan that reflects your device class, not a generic "12 months, 200k"?
  6. Have you done an explicit gap analysis of your MDR technical documentation against Japanese submission expectations?
  7. Is your QMS already aligned with Ministerial Ordinance No. 169 or do you have a plan to close the gap?
  8. Does your post-market surveillance SOP handle Japanese vigilance reporting through the MAH?

Frequently Asked Questions

Does Japan accept the CE mark? No. Japan has its own approval framework and does not automatically recognise CE marking. However, the work you did to earn a CE mark (technical documentation, risk management, clinical evaluation, QMS) is substantially reusable with gap-closing, translation and MAH-specific additions.

What is the difference between MAH and D-MAH? MAH is an in-house Japanese legal entity holding the approval directly. D-MAH is a third-party Japanese entity holding the approval on behalf of a foreign manufacturer. For EU startups entering Japan before building their own Japanese presence, D-MAH is the common route.

Do we need Japan-specific clinical data? It depends on device class, mechanism of action, and whether existing clinical data can be bridged to Japanese populations. Class IV implantables often require Japan-specific or Japan-inclusive data. Class II software or diagnostic devices can often rely on existing data with a justified bridging analysis.

How long does PMDA review take? It varies by pathway and class. Class I self-declaration is fast (weeks). Class II Ninsho (RCB) review is typically 3 to 6 months. Class III and IV Shonin (PMDA) review can range from 9 months to over 24 months depending on complexity and clarification rounds.

Is Japanese QMS certification separate from ISO 13485? The Japanese QMS requirements are set by MHLW Ministerial Ordinance No. 169, which aligns closely with ISO 13485. Conformity is typically assessed during the approval process and through periodic audits. For manufacturers already certified to EN ISO 13485:2016+A11:2021, the additional work focuses on Japan-specific records and MAH interface documentation.

How does this sequence with FDA clearance? Most EU startups who enter both the US and Japan do so in the order CE mark → FDA → Japan. FDA documentation is often easier to leverage into a Japanese submission than MDR documentation alone because Japanese reviewers are familiar with FDA submission formats and content structures. Sequencing Japan after FDA reduces duplication and risk.

What does Japan entry cost for a typical Class II software device? A realistic range for a Class II software device via Ninsho (RCB) pathway, using a D-MAH, is 150,000 to 350,000 EUR including D-MAH fees, translation, RCB fees, QMS alignment, internal time and travel. Class III and IV hardware can cost 10x more.

Sources

  1. Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics (PMD Act), Japan, current consolidated version.
  2. MHLW Ministerial Ordinance No. 169 on Quality Management Systems for Medical Devices (alignment with ISO 13485).
  3. PMDA official guidance documents on medical device review pathways (Ninsho and Shonin), current versions.
  4. Japanese Medical Device Nomenclature (JMDN) as maintained by MHLW and PMDA.